TABLE 3.
PET/CT Demonstration of Vaccination-Related Lymphadenopathy and Inflammation in 28 Examinees
| Examinee No. | Age, y | Sex | Interval, d | ALN Size, mm | ALN SUVmax | SCN SUVmax | Upper Arm LN SUVmax | Deltoid SUVmax |
|---|---|---|---|---|---|---|---|---|
| 1 | 40 | F | 4 | 6 | 3.8 | — | 2.7 | 2.1 |
| 2 | 40 | M | 4 | 8 | 5.0 | 2.9 | 3.8 | * |
| 3 | 40 | F | 4 | 8 | 7.6 | — | 2.4 | 2.6 |
| 4 | 50 | F | 4 | 9 | 6.6 | — | — | 3.7 |
| 5 | 44 | F | 6 | 9 | 3.2 | 2.4 | — | 5.4 |
| 6 | 44 | F | 9 | 6 | 5.4 | 3.4 | — | 2.6 |
| 7 | 39 | F | 9 | 6 | 3.8 | — | — | 2.2 |
| 8 | 44 | F | 11 | 8 | 4.1 | 3.4 | — | 3.0 |
| 9 | 40 | F | 11 | 5 | 2.2 | — | — | 2.6 |
| 10 | 44 | F | 12 | 7 | 2.9 | — | — | 3.6 |
| 11 | 55 | F | 12 | 9 | 8.0 | — | — | 5.2 |
| 12 | 50 | F | 12 | 6 | 2.6 | — | — | 2.7 |
| 13 | 44 | F | 12 | 6 | 3.9 | — | — | 2.2 |
| 14 | 40 | F | 12 | 7 | 3.2 | 2.5 | — | 3.4 |
| 15 | 60 | M | 14 | 7 | 2.4 | — | — | 2.6 |
| 16 | 49 | M | 14 | 6 | 4.1 | 1.5 | — | 3.0 |
| 17 | 49 | F | 14 | 8 | 6.3 | — | — | 2.6 |
| 18 | 49 | M | 14 | 7 | 3.9 | — | — | 2.7 |
| 19 | 49 | M | 14 | 7 | 2.0 | — | — | 1.6 |
| 20 | 40 | F | 15 | 8 | 3.6 | 2.4 | — | 2.4 |
| 21 | 40 | F | 21 | 7 | 5.3 | — | — | 1.6 |
| 22 | 49 | M | 22 | 4 | 2.0 | — | — | 1.2 |
| 23 | 41 | F | 23 | 6 | 5.4 | 1.6 | — | 2.0 |
| 24 | 40 | M | 23 | 8 | 2.4 | — | — | — |
| 25 | 40 | F | 26 | 4 | 2.5 | — | — | — |
| 26 | 45 | F | 27 | 5 | 2.8 | — | — | — |
| 27 | 44 | M | 28 | 4 | 3.2 | — | — | — |
| 28 | 49 | F | 29 | 6 | 2.3 | — | — | — |
ALN, axillary lymph node; SCN, supraclavicular lymph node; F, female; M, male.
*Presumed injection site of the upper arm not covered in the scan.